Kulkarni Tejaswini, Willoughby John, Acosta Lara Maria Del Pilar, Kim Young-Il, Ramachandran Rekha, Alexander C Bruce, Luckhardt Tracy, Thannickal Victor J, de Andrade Joao A
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States; Birmingham VA Medical Center, 700 South 19th Street, 6th Floor, Rm 6318, Birmingham, AL 35233, United States.
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States.
Respir Med. 2016 Jun;115:33-8. doi: 10.1016/j.rmed.2016.04.010. Epub 2016 Apr 20.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with poor prognosis and limited therapeutic options. The 2011 ATS/ERS/JRS/ALAT consensus statement provided a number of recommendations for the management of IPF patients. The primary objective of this study was to determine if "bundling" these recommendations in the management of patients with IPF impacts clinical outcomes. METHODS: We conducted a single center, retrospective cohort study of 284 patients diagnosed with IPF. The proposed bundle of care (BOC) components were: (1) visits to a specialized interstitial lung diseases clinic with evaluation of pulmonary function tests at least twice yearly; (2) referral to pulmonary rehabilitation yearly; (3) timed walk test yearly; (4) echocardiogram yearly; and (5) gastroesophageal reflux therapy. Each component of the BOC was given a score of "1" per year of follow up, and the average sum of the scores (ranging from 0 to 5) was determined for the entire period of follow-up (BOCS), as well as during the first year of follow-up (BOCY1). The primary outcome measure was transplant-free survival. RESULTS: Age, gender, smoking status, BMI, %FVC, %DLCO did not differ between levels of BOCS and BOCY1. Lowest BOCS (≤1) was associated with a lower transplant-free survival independent of age and %FVC compared to patients with the highest BOCS (>4) (HR 2.274, CI 1.12-4.64, p = 0.024). Lower BOCY1 was associated with a higher risk for transplant or death independent of age and %FVC in comparison to patients with highest BOCY1 (≤1 vs. >4, HR 2.23, p = 0.014; >1 to 2 vs. >4, HR 1.87, p = 0.011; >2 to 3 vs. >4, HR 1.72, p = 0.019). CONCLUSION: IPF patients with higher BOC scores had improved transplant-free survival. Prospective studies are needed to confirm these findings and determine the best strategies for the management of patients with IPF.
背景:特发性肺纤维化(IPF)是一种预后较差且治疗选择有限的慢性肺部疾病。2011年美国胸科学会(ATS)/欧洲呼吸学会(ERS)/日本呼吸学会(JRS)/拉丁美洲胸科协会(ALAT)的共识声明为IPF患者的管理提供了多项建议。本研究的主要目的是确定在IPF患者管理中“捆绑”这些建议是否会影响临床结局。 方法:我们对284例诊断为IPF的患者进行了一项单中心回顾性队列研究。拟议的综合照护方案(BOC)组成部分包括:(1)每年至少两次到专门的间质性肺病诊所就诊并评估肺功能测试;(2)每年转诊至肺康复治疗;(3)每年进行定时步行测试;(4)每年进行超声心动图检查;(5)胃食管反流治疗。BOC的每个组成部分在每年的随访中给予“1”分,并确定整个随访期间(BOCS)以及随访第一年(BOCY1)的平均得分总和(范围为0至5)。主要结局指标是无移植生存期。 结果:BOCS和BOCY1水平之间的年龄、性别、吸烟状况、体重指数、用力肺活量百分比(%FVC)、一氧化碳弥散量百分比(%DLCO)无差异。与BOCS最高(>4)的患者相比,BOCS最低(≤1)的患者独立于年龄和%FVC,其无移植生存期较低(风险比2.274,可信区间1.12 - 4.64,p = 0.024)。与BOCY1最高的患者相比,较低的BOCY1独立于年龄和%FVC,其移植或死亡风险更高(≤1与>4相比,风险比2.23,p = 0.014;>1至2与>4相比,风险比1.87,p = 0.011;>2至3与>4相比,风险比1.72,p = 0.019)。 结论:BOC得分较高的IPF患者无移植生存期得到改善。需要进行前瞻性研究以证实这些发现并确定IPF患者管理的最佳策略。
Zhonghua Jie He He Hu Xi Za Zhi. 2010-12
Int J Gen Med. 2015-9-22
N Engl J Med. 2014-5-18
N Engl J Med. 2014-5-18
Eur Respir J. 2011-10
Thorax. 2011-8-16